Weight‑loss medications like Wegovy and Ozempic continue to surge in popularity, with spending on GLP‑1 drugs increasing more than 500% between 2018 and 2023, according to the American Medical Association. The recent approval of Wegovy in pill form is expected to make these medications even more accessible.
While many patients have seen significant benefits, medical professionals are raising red flags. Dr. Marc Kaplan, Medical Director at Sweetser, notes that not all providers are adequately screening patients before prescribing these medications. His primary concern: individuals with undiagnosed eating disorders may be put at risk.
Watch Dr. Kaplan’s interview with WMTW’s Jacob Murphy:
Read the full article: Sweetser’s medical director weighs in on weight loss drugs